IT IS STILL POSSIBLE TO REGISTER FOR THIS COURSE!
In 2009, EFMC launched a series of short courses aimed to favour cultural and scientific growth of the medicinal chemistry community and organised with affordable fees for participation.
This intensive course is intended for scientists working in the field, and the presentations will be given by senior scientists from industry and academia. The number of participants will be limited to 35, to favour in depth discussion. Should the number of applications exceed the maximum, preference will be given to applicants from EFMC adhering countries and employees of EFMC corporate members. Upon special request to the organisers, only based on financial conditions and supported by an argued recommendation of the head of the department of the applicant, a limited number of applicants from academia (maximum 3) may be admitted at a reduced fee.
Protein-Protein Interactions (PPIs) lie at the heart of almost every physiological process and every disease. With a recently estimated number of 300,000 in humans, the possibilities for therapeutic intervention are significantly larger compared to ‘classical’ drug targets. While this potential is up to now largely untapped, some successful examples have shown that PPIs can be modulated by drug-like small molecules, natural products and peptides.
Specific features of PPIs as drug targets - in comparison to conventionally addressing e.g. enzymes - will be discussed, followed by a broad overview of the field, techniques to discover modulators of PPIs, and - in more detail - a number of case studies on successful PPI intervention will be presented. Speakers include a selection of top-scientists active in the field of PPI, both from industry and academia.
Christian OTTMANN and Luc BRUNSVELD, TU Eindhoven, The Netherlands
Henk TIMMERMAN, VU University Amsterdam, The Netherlands